Digital Biomarkers Market Size Report 2032: Enhancing Trial Efficiency, Accuracy, and Global Pharma Innovation

DelveInsight's Digital Biomarkers Market Insights Report 2032 provides the current and forecast market analysis, individual leading Digital Biomarkers Companies market shares, challenges, Digital Biomarkers Market Drivers, barriers, trends, and key market Digital Biomarkers companies in the market.

To read more about the latest highlights related to the Digital Biomarkers Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Digital Biomarkers Market Report
• In June 2025, Agenus and Noetik announced a collaboration to develop AI-enabled predictive biomarkers for BOT/BAL using foundation models of virtual cell biology. This partnership aims to advance precision immunotherapy by using AI-driven virtual cell models to identify patients most likely to benefit from BOT/BAL treatment.
• In March 2025, Lunit announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative AI applications in cancer research. The partnership focuses on developing AI-driven digital biomarkers for tumor microenvironment analysis and immune phenotyping, aiming to uncover insights from NCI data that could advance personalized cancer care.
• In March 2025, BostonGene announced a collaboration to evaluate biomarkers for colorectal cancer and multiple myeloma using AI-driven molecular profiling in clinical trials. This initiative aims to enhance cancer treatment strategies by leveraging advanced AI technologies to identify clinically relevant biomarkers.
• The digital biomarkers market was valued at USD 4,104.21 million in 2024, growing at a CAGR of 17.11% during the forecast period from 2025 to 2032 to reach USD 14,478.78 million by 2032.
• North America is projected to hold the largest share of the Digital Biomarkers market in 2024, driven by several key factors.
• The leading Digital Biomarkers Companies such as BioSensics, AliveCor, Inc., Eyenuk, Inc., Quibim, Huma, Evidation Health, Inc., Oura Health Oy, Biobeat, Omada Health Inc., F. Hoffmann-La Roche Ltd., Koneksa Health, Altoida, Empatica Inc., VivoSense, IXICO plc, Proscia Inc., Agenus Inc., Lunit, BostonGene Corporation, PathAI, Inc., and others.

To know more about why North America is leading the market growth in the Digital Biomarkers Market, get a snapshot @ Digital Biomarkers Market Outlook- https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Digital Biomarkers Market Dynamics
According to the British Heart Foundation (2024), approximately 640 million people globally were affected by heart and circulatory diseases, a number projected to rise in the coming years. Around 67 million new cases were diagnosed annually. In the UK alone, 1 in every 45 people (about 2 million) lived with heart rhythm-related conditions, with over 270,000 individuals undiagnosed. Similarly, the Australian Bureau of Statistics (2023) reported that 5% of Australians aged 55 and over suffered from atrial fibrillation. These figures highlighted the growing need for effective rhythm management therapies. Digital biomarkers, collected through wearable devices, offer continuous heart rhythm monitoring, enabling real-time detection of heart rhythm irregularities, thereby supporting market growth.

Digital Biomarkers Market Segmentation Analysis
Digital Biomarkers Market by Product Type (Wearable Devices, Implantable Devices, and Application/Software), Biomarker Type (Physiological Biomarkers, Behavioral Biomarkers, and Biochemical Biomarkers), Indication (Neurological Disease, Cardiovascular Disease, Metabolic Disease, and Others), Application (Diagnostic Biomarker, Monitoring Biomarker, and Predictive Biomarker), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the biomarker type segment of the digital biomarkers market, the physiological biomarkers category is estimated to account for the largest market share in 2024. This growth is primarily driven by the rising prevalence of chronic diseases, particularly cardiovascular and metabolic disorders, as well as the significant advantages that physiological biomarkers offer in disease detection and management.

Get a sneak peek at the Digital Biomarkers Market Dynamics @ Digital Biomarkers Market Dynamics Analysis- https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Digital Biomarkers Companies
BioSensics, AliveCor, Inc., Eyenuk, Inc., Quibim, Huma, Evidation Health, Inc., Oura Health Oy, Biobeat, Omada Health Inc., F. Hoffmann-La Roche Ltd., Koneksa Health, Altoida, Empatica Inc., VivoSense, IXICO plc, Proscia Inc., Agenus Inc., Lunit, BostonGene Corporation, PathAI, Inc., and others.

Digital Biomarkers Market Drivers
The growing demand for digital biomarkers is primarily driven by the rising global prevalence of chronic diseases, including cardiovascular, neurological, and metabolic disorders. A significant contributing factor is the expanding geriatric population, which is more vulnerable to these conditions due to age-related physiological decline. In addition, the increasing adoption of wearable devices, along with continuous product innovation and frequent new product launches among the leading market players, is further accelerating market growth. These combined trends are fostering a favourable environment for sustained development, positioning the digital biomarkers market for robust and steady growth during the forecast period from 2025 to 2032.

Which MedTech key players in the Digital Biomarkers Market are set to emerge as the trendsetter explore @ Digital Biomarkers Companies- https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Digital Biomarkers Market Report
• Coverage- Global
• Forecast Period- 2025-2032
• Digital Biomarkers Companies- BioSensics, AliveCor, Inc., Eyenuk, Inc., Quibim, Huma, Evidation Health, Inc., Oura Health Oy, Biobeat, Omada Health Inc., F. Hoffmann-La Roche Ltd., Koneksa Health, Altoida, Empatica Inc., VivoSense, IXICO plc, Proscia Inc., Agenus Inc., Lunit, BostonGene Corporation, PathAI, Inc., and others.

Interested in knowing the Digital Biomarkers Market by 2032? Click to get a snapshot of the Digital Biomarkers Market Trends- https://www.delveinsight.com/sample-request/digital-biomarkers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Digital Biomarkers Market Report Introduction
2. Digital Biomarkers Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Digital Biomarkers Market Key Factors Analysis
6. Digital Biomarkers Market Porter's Five Forces Analysis
7. Digital Biomarkers Market Assessment
8. Digital Biomarkers Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.